Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma

G. V. Long, A. Hauschild, M. Santinami, V. G. Atkinson, M. Mandala, V. Chiarion-Sileni, J. Larkin, C. Robert, D. Schadendorf, K. Dasgupta, M. Shilkrut, J. Garrett, J. C. Brase, R. Kefford, J. M. Kirkwood, R. Dummer

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article numberLBA43
Pages (from-to)viii734-viii735
Number of pages2
JournalAnnals of Oncology
Issue numberSupplement 8
Publication statusPublished - 1 Oct 2018
Event43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany
Duration: 19 Oct 201823 Oct 2018

Cite this